Eagle Asset Management Inc Incyte Corp Transaction History

Eagle Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 11, 2020	SELL	$63.18 - $85.97 $28.5 Million - $38.8 Million	-450,869 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$73.04 - $95.72 $606,232 - $794,476	8,300 Added 1.88%	450,869 $39.4 Million
Q3 2019 Nov 04, 2019	BUY	$72.82 - $86.52 $10,194 - $12,112	140 Added 0.03%	442,569 $32.9 Million
Q2 2019 Aug 05, 2019	BUY	$73.52 - $88.7 $261,290 - $315,239	3,554 Added 0.81%	442,429 $37.6 Million
Q1 2019 May 01, 2019	BUY	$63.56 - $88.17 $27.9 Million - $38.7 Million	438,875 New	438,875 $37.7 Million
Q2 2018 Aug 07, 2018	SELL	$60.85 - $83.98 $18.8 Million - $26 Million	-309,711 Closed	0 $0
Q1 2018 May 09, 2018	BUY	$83.06 - $100.98 $2.7 Million - $3.28 Million	32,521 Added 11.73%	309,711 $25.8 Million
Q4 2017 Feb 09, 2018	BUY	$93.56 - $116.6 $5.48 Million - $6.83 Million	58,569 Added 26.79%	277,190 $26.1 Million
Q3 2017 Nov 09, 2017	BUY	$109.15 - $138.27 $23.9 Million - $30.2 Million	218,621	218,621 $25.2 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.